New pill shows promise in early lung cancer trial
NCT ID NCT06905197
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new daily pill called DZD6008 in 140 people with advanced non-small cell lung cancer that has certain EGFR mutations. The main goals are to check the drug's safety and see if it can shrink tumors. Participants will take DZD6008 by mouth every day, and some may also receive another drug called sunvozertinib.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DZD6008 (a drug taken daily by mouth)
What this could lead to
If this works, it could point toward a new treatment option for people with advanced lung cancer that has specific EGFR mutations.
What could go wrong
This is a very early phase 1 trial, so the drug may not be effective or could have unexpected side effects. It is small and focused on safety, not proof of a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Blacktown Hospital
ACTIVE_NOT_RECRUITINGBlacktown, New South Wales, 2148, Australia
-
Chris O'Brien Lifehouse
NOT_YET_RECRUITINGCamperdown, New South Wales, 2050, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Herbert Irving Comprehensive Cancer Center
RECRUITINGNew York, New York, 10032, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Virginia Cancer Specialist (NEXT Oncology-Virginia)
ACTIVE_NOT_RECRUITINGFairfax, Virginia, 22031, United States